Gables Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Gables Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-275	Closed	-$10K	–	345
2022 Q2	$10K	Hold	275	–	–	0.01%	291
2022 Q1	$10K	Hold	275	–	–	0.01%	299
2021 Q4	$8K	Hold	275	–	–	﹤0.01%	307
2021 Q3	$9K	Hold	275	–	–	0.01%	301
2021 Q2	$11K	Hold	275	–	–	0.01%	292
2021 Q1	$12K	Hold	275	–	–	0.01%	312
2020 Q4	$16K	Hold	275	–	–	0.01%	285
2020 Q3	$13K	Hold	275	–	–	0.01%	291
2020 Q2	$16K	Hold	275	–	–	0.01%	268
2020 Q1	$13K	Buy	+275	New	+$15.3K	0.01%	277

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Gables Capital Management's IONS Position: Q3 2022 in Review

Gables Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 275 shares — an estimated $10K sold.

Gables Capital Management first reported a position in IONS in Q1 2020 and held it in 10 quarters. The position peaked at $16K in Q4 2020. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

Gables Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Gables Capital Management sold 275 Ionis Pharmaceuticals shares in Q3 2022, an estimated $10K.
Gables Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Gables Capital Management's Ionis Pharmaceuticals position peaked at $16K in Q4 2020.
349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Gables Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.